Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Deferred Revenue: 2017

Historic Current Deferred Revenue for UroGen Pharma (URGN) over the last 1 years, with Dec 2017 value amounting to $650,000.

  • UroGen Pharma's Current Deferred Revenue fell 72.35% to $86,000 in Q2 2018 from the same period last year, while for Jun 2018 it was $86,000, marking a year-over-year decrease of 72.35%. This contributed to the annual value of $650,000 for FY2017, which is N/A change from last year.
  • Per UroGen Pharma's latest filing, its Current Deferred Revenue stood at $650,000 for FY2017.
  • In the past 5 years, UroGen Pharma's Current Deferred Revenue registered a high of $650,000 during FY2017, and its lowest value of $650,000 during FY2017.
  • Moreover, its 1-year median value for Current Deferred Revenue was $650,000 (2017), whereas its average is $650,000.